2026 Q1 -tulosraportti
Vain PDF
58 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenGood summary related to the latest announcement from the company on June 25. Dicot Pharma announces that the FDA has reviewed the company's IND application and given the green light to initiate the first step in the Phase IIb study with the drug candidate LIB-01 in the USA. However, the authority requests additional tox data before the efficacy part of the study can start in the USA, which means that Dicot is bringing forward an already planned preclinical study. Study start is still planned for the second half of 2026. Erectile dysfunction and premature ejaculation affect over 500 million men globally and constitute a market valued at approximately 80 billion SEK. Despite this, existing treatments are perceived by many patients as insufficient — either due to short-acting effect or side effects. This is where Dicot sees its opportunity. LIB-01 is being developed with the ambition to offer significantly longer duration of action and better tolerability than today's alternatives, and the company continuously evaluates industrial and financial partnerships to bring the candidate to commercialization on the world market. Phase IIa showed evidence of clinically relevant and long-acting effects at both 25 mg and 50 mg, and Phase IIb builds on these results with three dose levels, where a higher dose is added to map the safety profile with repeated dosing. Green light for Part I — Part II awaits tox data Now the IND application is activated, and the FDA has approved the start of the first part of the study, Part I, where the maximum dose for efficacy evaluation is determined. The FDA has not questioned the clinical or preclinical safety documentation but wants to see results from a three-month tox study with repeated dosing before Part II can be initiated in the USA. Dicot chooses to bring forward this tox study, which was already in the plan, to keep the overall timeline intact. In Europe, a parallel process is underway, with an application for study start planned for the third quarter of 2026. – It is an important milestone and a quality stamp for our development work that the FDA, after its review of our IND application, has given the green light to initiate the initial step in the Phase IIb study for LIB-01. We are now continuing to work on applying for study start in Europe, says Elin Trampe, CEO of Dicot Pharma. https://biostock.se/2026/06/dicot-pharma-far-klartecken-fran-fda-for-fas-iib-studien-med-lib-01/
·2 päivää sittenResearch company Dicot Pharma has received clearance from the US Food and Drug Administration (FDA) to initiate the first part of the Phase 2b study with the drug candidate LIB-01 for the treatment of erectile dysfunction. This is stated in a press release.
·3 päivää sittenShort selling is going down
Be calm, short selling will increase as soon as it has gone up 20 % again. They milk shareholders who don't have the nerves to hold. It will fluctuate sharply until the drug is approved. There will be some real peaks and troughs until then. But if it gets approved, it will be a good investment.. many hundred percent up. That is my prophecy!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
58 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenGood summary related to the latest announcement from the company on June 25. Dicot Pharma announces that the FDA has reviewed the company's IND application and given the green light to initiate the first step in the Phase IIb study with the drug candidate LIB-01 in the USA. However, the authority requests additional tox data before the efficacy part of the study can start in the USA, which means that Dicot is bringing forward an already planned preclinical study. Study start is still planned for the second half of 2026. Erectile dysfunction and premature ejaculation affect over 500 million men globally and constitute a market valued at approximately 80 billion SEK. Despite this, existing treatments are perceived by many patients as insufficient — either due to short-acting effect or side effects. This is where Dicot sees its opportunity. LIB-01 is being developed with the ambition to offer significantly longer duration of action and better tolerability than today's alternatives, and the company continuously evaluates industrial and financial partnerships to bring the candidate to commercialization on the world market. Phase IIa showed evidence of clinically relevant and long-acting effects at both 25 mg and 50 mg, and Phase IIb builds on these results with three dose levels, where a higher dose is added to map the safety profile with repeated dosing. Green light for Part I — Part II awaits tox data Now the IND application is activated, and the FDA has approved the start of the first part of the study, Part I, where the maximum dose for efficacy evaluation is determined. The FDA has not questioned the clinical or preclinical safety documentation but wants to see results from a three-month tox study with repeated dosing before Part II can be initiated in the USA. Dicot chooses to bring forward this tox study, which was already in the plan, to keep the overall timeline intact. In Europe, a parallel process is underway, with an application for study start planned for the third quarter of 2026. – It is an important milestone and a quality stamp for our development work that the FDA, after its review of our IND application, has given the green light to initiate the initial step in the Phase IIb study for LIB-01. We are now continuing to work on applying for study start in Europe, says Elin Trampe, CEO of Dicot Pharma. https://biostock.se/2026/06/dicot-pharma-far-klartecken-fran-fda-for-fas-iib-studien-med-lib-01/
- ·2 päivää sittenResearch company Dicot Pharma has received clearance from the US Food and Drug Administration (FDA) to initiate the first part of the Phase 2b study with the drug candidate LIB-01 for the treatment of erectile dysfunction. This is stated in a press release.
- ·3 päivää sittenShort selling is going downBe calm, short selling will increase as soon as it has gone up 20 % again. They milk shareholders who don't have the nerves to hold. It will fluctuate sharply until the drug is approved. There will be some real peaks and troughs until then. But if it gets approved, it will be a good investment.. many hundred percent up. That is my prophecy!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
58 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenGood summary related to the latest announcement from the company on June 25. Dicot Pharma announces that the FDA has reviewed the company's IND application and given the green light to initiate the first step in the Phase IIb study with the drug candidate LIB-01 in the USA. However, the authority requests additional tox data before the efficacy part of the study can start in the USA, which means that Dicot is bringing forward an already planned preclinical study. Study start is still planned for the second half of 2026. Erectile dysfunction and premature ejaculation affect over 500 million men globally and constitute a market valued at approximately 80 billion SEK. Despite this, existing treatments are perceived by many patients as insufficient — either due to short-acting effect or side effects. This is where Dicot sees its opportunity. LIB-01 is being developed with the ambition to offer significantly longer duration of action and better tolerability than today's alternatives, and the company continuously evaluates industrial and financial partnerships to bring the candidate to commercialization on the world market. Phase IIa showed evidence of clinically relevant and long-acting effects at both 25 mg and 50 mg, and Phase IIb builds on these results with three dose levels, where a higher dose is added to map the safety profile with repeated dosing. Green light for Part I — Part II awaits tox data Now the IND application is activated, and the FDA has approved the start of the first part of the study, Part I, where the maximum dose for efficacy evaluation is determined. The FDA has not questioned the clinical or preclinical safety documentation but wants to see results from a three-month tox study with repeated dosing before Part II can be initiated in the USA. Dicot chooses to bring forward this tox study, which was already in the plan, to keep the overall timeline intact. In Europe, a parallel process is underway, with an application for study start planned for the third quarter of 2026. – It is an important milestone and a quality stamp for our development work that the FDA, after its review of our IND application, has given the green light to initiate the initial step in the Phase IIb study for LIB-01. We are now continuing to work on applying for study start in Europe, says Elin Trampe, CEO of Dicot Pharma. https://biostock.se/2026/06/dicot-pharma-far-klartecken-fran-fda-for-fas-iib-studien-med-lib-01/
- ·2 päivää sittenResearch company Dicot Pharma has received clearance from the US Food and Drug Administration (FDA) to initiate the first part of the Phase 2b study with the drug candidate LIB-01 for the treatment of erectile dysfunction. This is stated in a press release.
- ·3 päivää sittenShort selling is going downBe calm, short selling will increase as soon as it has gone up 20 % again. They milk shareholders who don't have the nerves to hold. It will fluctuate sharply until the drug is approved. There will be some real peaks and troughs until then. But if it gets approved, it will be a good investment.. many hundred percent up. That is my prophecy!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt